Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie Jane Davies, Louise Færch, Ole Kleist Jeppesen, Arash Pakseresht, Sue D. Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A. Wadden, Ildiko Lingvay
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1016/s0140-6736(21)00213-0
- Published
- Mar 1, 2021
- Venue
- The Lancet
- DOI
- 10.1016/s0140-6736(21)00213-0
- PubMed
- 33667417
- Categories
- Pharmacology and Obesity Treatment
- License
- cc-by-nc-nd
- Provenance
- openalex